Is there a role for inhaled ciclesonide in the treatment of COVID-19?

Salvi, Sundeep

doi:10.4103/lungindia.lungindia_473_20

Cited by 4 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports suggested that the virus penetrated alveolar cells, provoking lung injury and concurrently contaminated macrophages. Therefore, local inflammation could develop, and ciclesonide may presumably play a positive role in such conditions due to the virus causing serious cases (Salvi 2021 ). To date, no others inhaled steroids have shown antiviral activity against COVID-19, apart from ciclesonide.…”

Section: Mechanism Of Action In Covid-19mentioning

confidence: 99%

COVID-19 and corticosteroids: a narrative review

et al. 2022

View full text Add to dashboard Cite

It has been reported that corticosteroid therapy was effective in the management of severe acute respiratory syndrome (SARS) and the Middle East Respiratory Syndrome (MERS), and recently in coronavirus disease 2019 (COVID-19). Corticosteroids are potent anti-inflammatory drugs that mitigate the risk of acute respiratory distress syndrome (ARDS) in COVID-19 and other viral pneumonia, despite a reduction of viral clearance; corticosteroids inhibit the development of cytokine storm and multi-organ damage. The risk–benefit ratio should be assessed for critical COVID-19 patients. In conclusion, corticosteroid therapy is an effective way in the management of COVID-19, it reduces the risk of complications primarily acute lung injury and the development of ARDS. Besides, corticosteroid therapy mainly dexamethasone and methylprednisolone are effective in reducing the severity of COVID-19 and associated comorbidities such as chronic obstructive pulmonary diseases (COPD), rheumatoid arthritis, and inflammatory bowel disease (IBD).

show abstract

Section: Mechanism Of Action In Covid-19mentioning

confidence: 99%

COVID-19 and corticosteroids: a narrative review

et al. 2022

View full text Add to dashboard Cite

show abstract

Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients

Ali

Ghonimy

2021

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background Progressive fibrotic lung disease is one of the possible consequences of COVID-19 pulmonary pneumonia, and it is one of the most worrying long-term complications. Pulmonary fibrosis is associated with non-reversible lung dysfunction. The long-term lung changes of previous COVID-19 infection still not completely understood and should be included in further studies. The aim of this study is the early detection and prediction of patients whom may develop such serious complication, thus giving a chance for early introduction of anti-fibrotic drugs. Results From April 2020 to December 2020, 80 patients in Cairo, Egypt, who have clinical manifestations and confirmed COVID-19 by PCR, were evaluated by follow-up MDCT. CT image analysis was processed including comparative study using follow-up data (different radiological signs and residual fibrotic changes). Although there was no specific cause for post-COVID-19 lung fibrosis, there were some predicting factors such as old age, cigarette smoking, high CT severity score, and long-term mechanical ventilation. Conclusion Early detection of potential cases of post-COVID-19 pulmonary fibrosis may give a chance to prevent or at least modify such disabling complication.

show abstract

RNAi-mediated inhibition of SARS-CoV-2: applications and challenges

Sanyal,

Chaubey

2024

Future Virology

View full text Add to dashboard Cite

The global pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to ∼6.9 million deaths and affected ∼767 million people globally. The approved vaccines have contributed significantly in reducing disease severity and mortality. However, new infections post vaccination and the lack of specific antivirals have encouraged the research using multiple approaches to design novel therapeutics against COVID-19. Recent studies on the applications of RNAi against coronavirus provide substantial evidence on the prospects of this technique against SARS-CoV-2. Progress in the field of computational analysis and applications of multiple delivery methods also promises safe and effective implementation of RNAi against COVID-19. This review deals with the possible applications and challenges of RNAi against SARS-CoV-2.

show abstract

Is there a role for inhaled ciclesonide in the treatment of COVID-19?

Cited by 4 publications

References 11 publications

COVID-19 and corticosteroids: a narrative review

COVID-19 and corticosteroids: a narrative review

Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients

RNAi-mediated inhibition of SARS-CoV-2: applications and challenges

Contact Info

Product

Resources

About